ADC Therapeutics

What ADC Therapeutics does

ADC Therapeutics SA is a Swiss-domiciled, commercial-stage biopharmaceutical company founded in 2011 and listed on the NYSE (ticker: ADCT), focused on the development of antibody drug conjugates (ADCs) using a proprietary pyrrolobenzodiazepine (PBD) dimer payload platform. Its lead and only commercial product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC that received FDA accelerated approval in April 2021 and European Commission conditional approval in the same year for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior systemic therapies. ADC Therapeutics generates substantially all of its revenue from U.S. ZYNLONTA product sales (FY2025 net product revenue of $73.6 million), with the company headquartered in Epalinges, Switzerland and operating a U.S. subsidiary in New Providence, New Jersey.

The company is pursuing label expansion through two principal clinical trials: the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab versus R-GemOx in second-line DLBCL (which met its PFS primary endpoint with reported safety signals including 27 patient deaths in the treatment arm), and the Phase 1b LOTIS-7 trial combining ZYNLONTA with Roche's CD20xCD3 bispecific glofitamab, which reported 90% overall response and 78% complete response rates. Beyond ZYNLONTA, the disclosed pipeline consists of a next-generation PSMA-targeting exatecan-based ADC (ADCT-601) in IND-enabling activities, with earlier programs ADCT-212 and ADCT-701 discontinued. Distribution is handled through specialty pharmacies supported by an Advancing Patient Support portal, with commercial engagement driven by a focused sales force and medical affairs team targeting oncologists and hematologists.

The business model is a single-asset, product-sales biopharmaceutical model funded by repeated equity raises (~$265M across 2024-2025) and a $300M HealthCare Royalty financing agreement amended in February 2026 to reduce the change-of-control obligation from $750M to $150M. The company reported a $142.6M FY2025 net loss and announced a 17% workforce reduction in June 2026 to deliver approximately $10M in annualized savings, with management guiding to a potential ZYNLONTA relaunch in 2027 once LOTIS-5/7 readouts are absorbed. Cash and cash equivalents stood at $261.3M at year-end 2025 and $231.0M at end of Q1 2026, supporting an operating runway into 2028.

Name

ADC Therapeutics

Legal name

ADC Therapeutics SA

Website

https://adctherapeutics.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

251–500 employees

Short description

ADC Therapeutics is a Swiss-listed biopharmaceutical company (NYSE: ADCT) that develops antibody drug conjugates using proprietary PBD technology, commercializing ZYNLONTA for relapsed/refractory diffuse large B-cell lymphoma and expanding into earlier lines and combinations.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Antibody drug conjugates
• Oncology therapeutics
• Cancer drug development
• Hematologic cancer treatment
• Biopharmaceutical products

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. ZYNLONTA Product Sales: Commercial-stage biopharmaceutical company generating revenue from sales of ZYNLONTA (loncastuximab tesirine-lpyl), its FDA-approved antibody drug conjugate for treatment of relapsed or refractory diffuse large B-cell lymphoma. Q4 2025 net product revenue of $22.3 million, full-year 2025 revenue of $73.6 million.
2. PIPE Financings: Private placement investments including $60 million PIPE financing (October 2025) and $100 million private placement (June 2025) to support clinical development and commercialization.
3. Royalty Financing: HealthCare Royalty financing agreement amended to reduce change of control payment obligation in exchange for warrants. Original agreement involved $300 million in funding.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

ADC Therapeutics is a commercial-stage biopharmaceutical company that develops antibody drug conjugates (ADCs) using proprietary pyrrolobenzodiazepine (PBD) dimer warhead technology. Its approved and commercialized product is ZYNLONTA (loncastuximab tesirine-lpyl), an FDA- and European Commission-approved CD19-directed ADC for adults with relapsed or refractory diffuse large B-cell lymphoma after two or more prior systemic therapies. Revenue is generated primarily through ZYNLONTA product sales via specialty pharmacy distribution.

Product overview

ADC Therapeutics is a commercial-stage biopharmaceutical company focused on antibody drug conjugates (ADCs) with proprietary PBD (pyrrolobenzodiazepine) warhead technology. The company's lead product is ZYNLONTA (loncastuximab tesirine-lpyl), an FDA-approved CD19-directed ADC for relapsed/refractory DLBCL. The company is expanding ZYNLONTA into earlier lines of therapy and indolent lymphomas through multiple clinical trials including LOTIS-5 (Phase 3) and LOTIS-7 (Phase 1b combination with glofitamab). The pipeline also includes a next-generation PSMA-targeting exatecan-based ADC in development, while discontinued programs include ADCT-212 and ADCT-701. ADC Therapeutics operates with strategic collaborations for co-development and academic partnerships in ADC research.

Differentiator

Problem solved

Functional benefit

Brands

• ZYNLONTA: CD19-directed antibody drug conjugate (ADC) using pyrrolobenzodiazepine (PBD) technology, approved for relapsed or refractory diffuse large B-cell lymphoma
• PBD Technology

Products and services

• ZYNLONTA (loncastuximab tesirine-lpyl) FDA- and European Commission-approved CD19-directed antibody drug conjugate (ADC) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior systemic therapies. It uses proprietary pyrrolobenzodiazepine (PBD) dimer warhead technology to deliver a potent cytotoxic payload directly to CD19-expressing tumor cells. Prescribed by hematologists and oncologists and distributed through specialty pharmacies, with patient access supported via the Advancing Patient Support program.
• ADC Therapeutics Partnering Programs Strategic collaborations offering industry partners access to ADC Therapeutics' proprietary PBD technology platform for co-development of antibody drug conjugates, as well as research collaborations with academic and industry scientists on novel ADC technologies. Includes co-development, research collaboration, and academic study partnerships across the ADC field.

Quantifiable outcome

• Phase 3 LOTIS-5 met primary endpoint of progression-free survival (HR=0.73; p=0.008) with median PFS of 6.1 months vs 4.7 months for R-GemOx regimen
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Roche (Glofitamab/Columvi)coreStrategic or Co-development PartnerLOTIS-7 Phase 1b trial evaluates ZYNLONTA in combination with Roche's glofitamab (COLUMVI) bispecific antibody for relapsed or refractory B-cell non-Hodgkin lymphoma. Demonstrated 90% overall response rate and 78% complete response rate in clinical trials.

Scale indicators13 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• ImmunoGen (AbbVie subsidiary): Direct ADC competitor acquired by AbbVie in 2024 for $10.1B; developed ELAHERE, an FDA-approved ADC for ovarian cancer. Highly comparable as a similarly-sized, single-product commercial-stage ADC company with a linker-payload platform.
• Seagen (Pfizer subsidiary): Leading commercial ADC company acquired by Pfizer for $43B; developed Adcetris, Padcev, Tukysa, and Tivdak. Direct comparator given its ADC technology platform and hematologic/oncology focus.
• Daiichi Sankyo: Japanese pharmaceutical leader in ADC technology with DXd payload platform; developed Enhertu and Datroway in partnership with AstraZeneca. Most relevant peer for ADC platform monetization and pipeline depth.
• Takeda Pharmaceutical: Develops and markets Adcetris (with Seagen) for lymphoma; has broad ADC ambitions. Direct comparator in hematologic cancer ADCs with global commercial reach.
• Genmab: Develops bispecific antibodies (epcoritamab/talquetamab) in DLBCL; competes in the same indication as ZYNLONTA via different modality. Emerging player with overlapping hematology-oncology focus.

Broad incumbents

• AstraZeneca: Global oncology leader and ADC partner via Enhertu/Datroway collaboration with Daiichi Sankyo; has AstraZeneca board representation at ADC Therapeutics (Tyrell Rivers). Broad incumbent with overlapping ADC ambitions.
• Roche: Strategic partner via LOTIS-7 combination with glofitamab (COLUMVI); also a leading oncology incumbent with bispecific antibodies and CAR-T pipelines (Lunsumio, Tecartus) that compete in DLBCL.
• Pfizer: Acquired Seagen for $43B to build ADC franchise; operates oncology portfolio including CAR-Ts and ADCs that overlap with ADC Therapeutics' hematologic oncology focus. Provides read-through to strategic value of ADC platforms.
• AbbVie: Acquired ImmunoGen and its ADC franchise; major oncology incumbent. Provides strategic-acquirer comparable for ADC Therapeutics given its single-product commercial profile.
• Bristol Myers Squibb: Major oncology incumbent with Breyanzi (lisocabtagene maraleucel) CAR-T for DLBCL and a broad hematology pipeline; competes with ZYNLONTA in r/r DLBCL and serves as a benchmark large-pharma oncology franchise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/adctherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds13 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ADC Therapeutics